Tango Therapeutics Inc (TNGX) News

Form S-8 - Securities to be offered to employees in employee benefit plans

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Form 8-K - Current report

Tango Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Highlights 

– TNG462 granted Orphan Drug Designation for treatment of pancreatic cancer – – Investigational New Drug (IND...

Tango Therapeutics to Present at Three Upcoming Investment Bank Conferences

BOSTON, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Feb. 20, 2025-- Tango Therapeutics, Inc. (NASDAQ: TNGX), a...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Tango Therapeutics to Present at the Guggenheim SMID Cap Biotechnology Conference

BOSTON, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage...

Form 8-K - Current report

Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of...

Tango Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference

Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of...

Form SC 13G - Statement of Beneficial Ownership by Certain Investors